Vichinsky, E., Bernaudin, F., Forni, G. L., Gardner, R., Hassell, K., Heeney, M. M., . . . Coates, T. (2011). Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Blackwell Publishing Ltd.
Styl cytowania ChicagoVichinsky, Elliott, et al. Long-term Safety and Efficacy of Deferasirox (Exjade®) for Up to 5 Years in Transfusional Iron-overloaded Patients With Sickle Cell Disease. Blackwell Publishing Ltd, 2011.
Styl cytowania MLAVichinsky, Elliott, et al. Long-term Safety and Efficacy of Deferasirox (Exjade®) for Up to 5 Years in Transfusional Iron-overloaded Patients With Sickle Cell Disease. Blackwell Publishing Ltd, 2011.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..